The targeted oncology drug developer, which counts Bristol Myers Squibb and Celgene as investors, is floating above its range in an upsized offering.

Rabies and meningities vaccine producer Kanghua Biological, which counts Aokang and Tigermed as investors, has floated in its home country of China.

New World Development and China Mobile Games and Entertainment will have the chance to exit the Asia-based gay dating app developer.

TU Delft and Imperial-founded genetic data analytics software provider BlueBee has been picked up after raising at least $13.5m of funding.

The Alphabet-backed smart vending operator is set to close down in the next two weeks having been valued at $100m in its last round.

Chalmers Ventures portfolio company Biofrigas has set out plans for a $1.7m IPO but has already issued around $1.2m to existing connections.

Novartis and Eli Lilly are set to score exits from the cancer and blood disease drug developer in an initial public offering set to raise up to $212m.

The move came after the digital health technology provider, which has a raft of corporate investors, reportedly failed to raise a nine-figure round last year.

The Legend Holdings and Eli Lilly-backed cancer diagnostics technology developer floated above its range to raise $223m and its shares have since risen 40%.

Vaccine developer Vaxcyte has floated in an upsized initial public offering having raised $110m in a Roche-backed round just three months ago.